Preclinical validation of electrochemotherapy as an effective treatment for brain tumors

Cancer Research

Volumn 71, Issue 11, 2011, Pages 3753-3762

  Agerholm Larsen, Birgit ^a,b   Iversen, Helle K ^a,b   Ibsen, Per ^a   Moller, Jakob M ^a   Mahmood, Faisal ^a   Jensen, Kurt Svarre ^a,b   Gehl, Julie ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; CYTOSOL; DRUG ADMINISTRATION ROUTE; DRUG TRANSPORT; ELECTRIC FIELD; ELECTROCHEMOTHERAPY; ELECTRODE; ELECTROPORATION; EVALUATION RESEARCH; GLIA CELL; GLIOMA; HISTOPATHOLOGY; INTRACELLULAR TRANSPORT; INTRACRANIAL DRUG ADMINISTRATION; LOCAL THERAPY; MALE; MONOTHERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RAT; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR NECROSIS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; BRAIN NEOPLASMS; ELECTROCHEMOTHERAPY; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; RATS; RATS, INBRED F344; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS;

EID: 79957907494     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-0451     Document Type: Article

References (50)

1. Smedby KE, Brandt L, Backlund ML, Blomqvist P. Brain metastases admissions in Sweden between 1987 and 2006. Br J Cancer 2009;101:1919-24.
2. Nussbaum ES, Djalilian HR, Cho KH, Hall WA. Brain metastases-histology, multiplicity, surgery, and survival. Cancer 1996;78:1781-8. (Pubitemid 26330907)
3. Ellis TL, Garcia PA, Rossmeisl JH, Henao-Guerrero N, Robertson J, Davalos RV. Nonthermal irreversible electroporation for intracranial surgical applications. J Neurosurg 2011;114:681-8.
4. Garcia PA, Pancotto T, Rossmeisl JH Jr, Henao-Guerrero N, Gustafson NR, Daniel GB, et al. Nonthermal irreversible electroporation (N-TIRE) and adjuvant fractionated radiotherapeutic multimodal therapy for intracranial malignant glioma in a canine patient. Technol Cancer Res Treat 2011;10:73-83.
5. Matthiessen LW, Muir T, Gehl J. Electrochemotherapy for larger malignant tumors. In: Kee S, Gehl J, Lee E, editors. Clinical aspects of electroporation. New York: Springer; 2011. p. 103-13.
6. Sersa G, Gehl J, Garbay J, Soden D, O'Sullivan G, Matthiessen LW, et al. Electrochemotherapy of small tumors; The experience from the ESOPE (European Standard Operating Procedures for Electrochemotherapy) Group. In: Kee S, Gehl J, Lee E, editors. Clinical aspects of electroporation. New York: Springer; 2011. p. 93-102.
7. Thomson K, Kee S. Clinical research on irreversible electroporation. In: Kee S, Gehl J, Lee E, editors. Clinical aspects of electroporation. New York: Springer; 2011. p. 237-46.
8. Garcia PA, Rossmeisl JH, Neal RE, Ellis TL, Olson JD, Henao-Guerrero N, et al. Intracranial nonthermal irreversible electroporation: in vivo analysis. J Membr Biol 2010;236:127-36.
9. Neal E, Rossmeisl JH Jr, Garcia PA, Lanz OI, Henao-Guerrero N, Davalos RV. Successful treatment of a large soft tissue sarcoma with irreversible electroporation. J Clin Oncol 2011;29:e372-7.
10. Gothelf A, Eriksen J, Hojman P, Gehl J. Duration and level of transgene expression after gene electrotransfer to skin in mice. Gene Ther 2010;17:839-45.
11. Silve A, Mir LM. Cell electropermeabilization and cellular uptake of small molecules: The electrochemotherapy concept. In: Kee S, Gehl J, Lee E, editors. Clinical aspects of electroporation. New York: Springer; 2011. p. 69-82.
12. Gehl J. Electroporation for drug and gene delivery in the clinic: doctors go electric. In: Electroporation protocols, preclinical and clinical gene medicine. Totowa, NJ: Humana Press; 2008. p. 351-9.
13. Kaufman CD, Geiger RC, Dean DA. Electroporation- and mechanical ventilation-mediated gene transfer to the lung. Gene Ther 2010;17:1098-104.
14. Mir LM, Moller PH, Andre F, Gehl J. Electric pulse-mediated gene delivery to various animal tissues. Adv Genet 2005;54:83-114. (Pubitemid 43580687)
15. Rols MP. Gene transfer by electrical fields. Curr Gene Ther 2010;10:255.
16. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008;26:5896-903.
17. Golzio M, Teissie J, Rols MP. Direct visualization at the single-cell level of electrically mediated gene delivery. Proc Natl Acad Sci U S A 2002;99:1292-7. (Pubitemid 34136486)
18. Heller LC, Heller R. Electroporation gene therapy preclinical and clinical trials for melanoma. Curr Gene Ther 2010;10:312-7.
19. Hojman P, Gissel H, Gehl J. Sensitive and precise regulation of haemoglobin after gene transfer of erythropoietin to muscle tissue using electroporation. Gene Ther 2007;14:950-9. (Pubitemid 46865506)
20. Mir LM, Bureau MF, Gehl J, Rangara R, Rouy D, Caillaud JM, et al. High-efficiency gene transfer into skeletalmuscle mediated by electric pulses. Proc Natl Acad Sci U S A 1999;96:4262-7. (Pubitemid 29190324)
21. Gehl J. Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol 2003;177:437-47. (Pubitemid 36411581)
22. Gothelf A, Mir LM, Gehl J. Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev 2003;29:371-87. (Pubitemid 37185104)
23. Jaroszeski MJ, Gilbert R, Heller R. Electrochemotherapy: an emerging drug delivery method for the treatment of cancer. Adv Drug Deliv Rev 1997;26:185-97. (Pubitemid 27289533)
24. Mir LM. Therapeutic perspectives of in vivo cell electropermeabilization. Bioelectrochemistry 2001;53:1-10. (Pubitemid 32015625)
25. Marty M, Sersa G, Garbay JR, Gehl J, Collins CG, Snoj M, et al. Electrochemotherapy-an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. Eur J Cancer Supplements 2006;4:3-13. (Pubitemid 44755131)
26. Fini M, Tschon M, Ronchetti M, Cavani F, Bianchi G, Mercuri M, et al. Ablation of bone cells by electroporation. J Bone Joint Surg Br 2010;92:1614-20.
27. Kos B, Zupanic A, Kotnik T, Snoj M, Sersa G, Miklavcic D. Robustness of treatment planning for electrochemotherapy of deep-seated tumors. J Membr Biol 2010;236:147-53.
28. Einhorn LH. Curing metastatic testicular cancer. Proc Natl Acad Sci U S A 2002;99:4592-5. (Pubitemid 34286029)
29. Linnert M, Gehl J. Bleomycin treatment of brain tumors: an evaluation. Anticancer Drugs 2009;20:157-64.
30. Belehradek M, Domenge C, Luboinski B, Orlowski S, Belehradek J, Mir LM. Electrochemotherapy, a new antitumor treatment. First clinical phase-I-II trial. Cancer 1993;72:3694-700.
31. Glass LF, Jaroszeski M, Gilbert R, Reintgen DS, Heller R. Intralesional bleomycin-mediated electrochemotherapy in 20 patients with basal cell carcinoma. J Am Acad Dermatol 1997;37:596-9. (Pubitemid 27446731)
32. Heller R, Jaroszeski MJ, Glass LF, Messina JL, Rapaport DP, DeConti RC, et al. Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy. Cancer 1996;77:964-71. (Pubitemid 26061293)
33. Tounekti O, Kenani A, Foray N, Orlowski S, Mir LM. The ratio of single-to double-strand DNA breaks and their absolute values determine cell death pathway. Br J Cancer 2001;84:1272-9. (Pubitemid 32511347)
34. Salford LG, Persson BRR, Brun A, Ceberg CP, Kongstad PC, Mir LM. A new brain-tumor therapy combining bleomycin with in vivo electropermeabilization. Biochem Biophys Res Commun 1993;194:938-43. (Pubitemid 23245225)
35. Siesjo P, Visse E, Lindvall M, Salford L, Sjogren HO. Immunization with mutagen-treated (Tum-) cells causes rejection of nonimmunogenic rat glioma isografts. Cancer Immunol Immunother 1993;37:67-74. (Pubitemid 23159727)
36. Bexell D, Gunnarsson S, Siesjo P, Bengzon J, Darabi A. CD133+and nestin plus tumor-initiating cells dominate in N29 and N32 experimental gliomas. Int J Cancer 2009;125:15-22.
37. Attia MA, Deome KB, Weiss DW. Immunology of spontaneous mammary carcinomas in mice.II. Resistance to a rapidly and a slowly developing tumor. Cancer Res 1965;25:451-7.
38. Domenge C, Orlowski S, Luboinski B, DeBaere T, Schwaab G, Belehradek J, et al. Antitumor electrochemotherapy: new advances in the clinical protocol. Cancer 1996;77:956-63. (Pubitemid 26061292)
39. Gehl J, Videbaek K,inventors, Electrode Introducer Device. Patent PCT/DK2007/050069. 2009.
40. Mahmood F, Hansen RH, Agerholm-Larsen B, Jensen KS, Iversen HK, Gehl J. Diffusion-weighted MRI for verification of electroporation-based treatments. J Membr Biol 2011;240:131-8.
41. Heller R, Jaroszeski MJ, Reintgen DS, Puleo CA, DeConti RC, Gilbert RA, et al. Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer 1998;83:148-57. (Pubitemid 28299641)
42. Mahmood F, Gehl J. Optimizing clinical performance and geometrical robustness of a new electrode device for intracranial tumor electroporation. Bioelectrochemistry 2011;81:10-6.
43. Matthiessen LW, Chalmers RL, Sainsbury DCG, Veeramani S, Kessel G, Bond J, et al. Management of cutaneous metastases using electrochemotherapy. Acta Oncol 2011;50:621-9.
44. Gehl J, Sørensen TH, Nielsen K, Raskmark P, Nielsen SL, Skovsgaard T, et al. In vivo electroporation of skeletal muscle: threshold, efficacy and relation to electric field distribution. Biochim Biophys Acta 1999;1428:233-40.
45. Miklavcic D, Beravs K, Semrov D, Cemazar M, Demsar F, Sersa G. The importance of electric field distribution for effective in vivo electroporation of tissues. Biophys J 1998;74:2152-8. (Pubitemid 28225212)
46. Miklavcic D, Snoj M, Zupanic A, Kos B, Cemazar M, Kropivnik M, et al. Towards treatment planning and treatment of deep-seated solid tumors by electrochemotherapy. Biomed Eng Online 2010;9:10.
47. Mekid H, Tounekti O, Spatz A, Cemazar M, El Kebir FZ, Mir LM. In vivo evolution of tumour cells after the generation of double-strand DNA breaks. Br J Cancer 2003;88:1763-71.
48. Sersa G, Cemazar M. Vascular disrupting action of electrochemotherapy: mode of action and therapeutic implications. In: Kee S, Gehl J, Lee E, editors. Clinical aspects of electroporation. New York: Springer; 2011. p. 83-91.
49. Muir T, Kirsten M, Fourie P, Dippenaar N, Ionescu GO. Intralesional bleomycin injection (IBI) treatment for haemangiomas and congenital vascular malformations. Pediatr Surg Int 2004;19:766-73. (Pubitemid 38387457)
50. Cemazar M, Parkins CS, Holder AL, Chaplin DJ, Tozer GM, Sersa G. Electroporation of human microvascular endothelial cells: evidence for an antivascular mechanism of electrochemotherapy. Br J Cancer 2001;84:565-70. (Pubitemid 32215887)